Adaptimmune Therapeutics Plc (ADAP) Gross Profit Margin starting from the second quarter 2025 to second quarter 2024, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Adaptimmune Therapeutics Plc  (NASDAQ: ADAP)


Adaptimmune Therapeutics Plc's Gross Profit Margin by quarter

Trends, Rankings, Statistics


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ADAP Gross Profit Margin (Jun 30 2025)
Q2 		(Mar 31 2025)
Q1 		(Dec 31 2024)
Q4 		(Sep 30 2024)
Q3 		(Jun 30 2024)
Q2
Y / Y Revenue Change -89.33 %
Seq. Revenue Change 87.74 %
Revenue In Millions $13.68
Gross Profit Margin 81.71 %
Gross Profit Margin Total Ranking # 575
Gross Profit In Millions $11.18
Y / Y Gross Profit Change -
Seq. Gross Profit Change 74.46 %


Commenting Second Quarter 2025 Gross Profit Margin
Adaptimmune Therapeutics Plc has managed to improve its Revenue sequentially to $13.68 millions by 87.74 % faster than Gross Profit increase of 74.46 % to $11.18 millions, this led to contraction in Gross Profit Margin to 81.71 %, a new company low.


Observing second quarter 2025 results within Biotechnology & Pharmaceuticals industry 13 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin overall ranking has deteriorated relative to the three months before, from 451 to 575.
Learn about Gross Margin
ADAP's Gross Profit Margin second quarter 2025 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 14
Healthcare Sector # 99
Overall # 569

Gross Profit Margin Statistics
High Average Low
87.93 % 84.82 % 81.71 %
(Mar 31 2025)   (Jun 30 2025)


ADAP Gross Income Trends • More of ADAP's Profitabilty Ratios • ADAP Stock Quotes and Charts


Other Gross Profit Margin Profitability Ratios
ADAP's Cumulative Gross Profit Margin
Biotechnology & Pharmaceuticals Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
ADAP's Gross Profit Margin Profitability versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for ADAP's Competitors
Gross Profit Margin Profit Margin for Adaptimmune Therapeutics Plc's Suppliers
Gross Profit Margin Profit Margin for ADAP's Customers

You may also want to know
ADAP's Annual Growth Rates ADAP's Profitability Ratios ADAP's Asset Turnover Ratio ADAP's Dividend Growth
ADAP's Roe ADAP's Valuation Ratios ADAP's Financial Strength Ratios ADAP's Gross Profit Growth
ADAP's Roa ADAP's Inventory Turnover Ratio ADAP's Growth Rates ADAP's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Jun 30 2025, within Biotechnology & Pharmaceuticals Industry Gross Profit MarginJun 30 2025 MRQ Gross ProfitJun 30 2025 MRQ Revenue
Immunitybio inc   99.49 %$ 26.289  Millions$ 26.425  Millions
Vir Biotechnology Inc   99.09 %$ 1.203  Millions$ 1.214  Millions
Agenus Inc  99.05 %$ 25.448  Millions$ 25.691  Millions
Immunocore Holdings Plc  98.94 %$ 96.924  Millions$ 97.964  Millions
Neurocrine Biosciences Inc   98.36 %$ 676.200  Millions$ 687.500  Millions
Biocryst Pharmaceuticals Inc   98.29 %$ 160.555  Millions$ 163.353  Millions
Exelixis Inc   96.57 %$ 548.791  Millions$ 568.261  Millions
Novavax inc   93.59 %$ 223.915  Millions$ 239.240  Millions
Alpha Cognition Inc.  87.70 %$ 1.454  Millions$ 1.658  Millions
Halozyme Therapeutics Inc   85.77 %$ 279.360  Millions$ 325.719  Millions
X4 Pharmaceuticals Inc  83.48 %$ 1.647  Millions$ 1.973  Millions
Zeo Scientifix Inc   82.54 %$ 1.078  Millions$ 1.306  Millions
Adaptimmune Therapeutics Plc  81.71 %$ 11.176  Millions$ 13.677  Millions
Ginkgo Bioworks Holdings Inc   80.97 %$ 40.162  Millions$ 49.604  Millions
Gilead Sciences Inc   78.81 %$ 5,581.000  Millions$ 7,082.000  Millions
Biogen Inc   77.13 %$ 2,040.500  Millions$ 2,645.500  Millions
Vericel Corporation  73.71 %$ 46.613  Millions$ 63.240  Millions
Outlook Therapeutics Inc   70.78 %$ 1.066  Millions$ 1.505  Millions
Mesoblast Limited  70.17 %$ 12.068  Millions$ 17.198  Millions
Adaptive Biotechnologies Corporation  69.43 %$ 40.880  Millions$ 58.879  Millions
Xtant Medical Holdings Inc   68.82 %$ 24.284  Millions$ 35.284  Millions
Amgen Inc   67.20 %$ 6,168.000  Millions$ 9,179.000  Millions
Scilex Holding Company  66.94 %$ 6.624  Millions$ 9.896  Millions
Coherus Oncology inc   66.89 %$ 6.859  Millions$ 10.254  Millions
Bio techne Corp  62.56 %$ 198.813  Millions$ 317.813  Millions
Protalix Biotherapeutics inc   62.51 %$ 9.788  Millions$ 15.658  Millions
Aim Immunotech Inc   60.00 %$ 0.015  Millions$ 0.025  Millions
Adma Biologics Inc   55.46 %$ 67.227  Millions$ 121.227  Millions
Twist Bioscience Corporation  53.40 %$ 51.297  Millions$ 96.057  Millions
Pluri Inc   52.01 %$ 0.207  Millions$ 0.398  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.